Aspirin in type 2 diabetes, a randomised controlled study: Effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function

International Journal of Clinical Practice

Volumn 68, Issue 2, 2014, Pages 271-277

  Raghavan, R P ^a,b,c   Laight, D W ^b   Cummings, M H ^c  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FRUCTOSAMINE; GLUTATHIONE; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; FEMALE; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; LIPID ANALYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHOTOELECTRIC PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT DURATION; VASCULITIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; GLUTATHIONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OXIDATIVE STRESS; VASCULITIS;

EID: 84893646664     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12310     Document Type: Article

References (30)

1. Coleman RL, Stevens RJ, Retnakaran R, Holman RR,. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 2007; 30: 1292-3.
2. Tracy RP,. Inflammation, the metabolic syndrome and cardiovascular risk [Review]. Int J Clin Pract Suppl 2003; 27: 10-7.
3. Haffner S, D'Agostino R, Mykkanen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-8.
4. Costanzo A, Moretti F, Burgio VL, et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003; 195: 402-10.
5. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-6.
6. Ristimae T, Zilmer M, Zilmer K, Kairane C, Kullisaar T, Teesalu R,. Effect of low-dose aspirin on the markers of oxidative stress. Cardiovasc Drugs Ther 1999; 13: 485-90.
7. Reilly M, Delanty N, Lawson JA, FitzGerald GA,. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19-25.
8. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196: 1025-37.
9. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002; 105: 2600-4.
10. Hermann M, Kapiotis S, Hofbauer R, et al. Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals. FEBS Lett 1999; 445: 212-4.
11. Holvoet P, Stassen JM, Van Cleemput J, Collen D, Vanhaecke J,. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 100-7.
12. Cominacini L, Rigoni A, Pasini AF, et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001; 276: 13750-5.
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
14. Pignone M, Alberts MJ, Colwell JA, et al. American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33: 1395-402.
15. Belch J, MacCuish A, Campbell I, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
16. Chowienczyk PJ, Kelly RP, MacCallum H, et al. Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus. J Am Coll Cardiol 1999; 34: 2007-14.
17. Wallace TM, Levy JC, Matthews DR,. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
18. Ledue TB, Weiner DL, Sipe J, Poulin SE, Collins MF, Rifai N,. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose-binding protein in human serum. Clin Chem 1997; 43: S240.
19. Benzie IF, Strain JJ,. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996; 239: 70-6.
20. Laight D, Gunnarsson P, Kaw A, Carrier M,. Physiological microassay of plasma total antioxidant status in a model of endothelial dysfunction in the rat following experimental oxidant stress in vivo. Environ Toxicol Chem 1999; 7: 27-31.
21. Tietze F,. Enzymic method for quantitative determination of nanogram amounts of total and oxidised glutathione. Anal Biochem 1969; 27: 502-22.
22. Cleanthis M, Smout J, Bhattacharya V, Ashour H, Shenton B, Stansby G,. Treadmill exercise in claudicants on aspirin results in improved antioxidant status but only minimal platelet activation. Platelets 2005; 16: 446-52.
23. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102: 1007-13.
24. Viinikka L,. Acetylsalicylic acid and the balance between prostacyclin and thromboxane A2. Scand J Clin Lab Invest Suppl 1990; 201: 103-8.
25. Juhlin T, Jönsson BA, Höglund P,. Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg. Eur J Heart Fail 2008; 10: 892-8.
26. Cao G, Prior RL,. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998; 44: 1309-15.
27. Buerke M, Pittroff W, Meyer J, Darius H,. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995; 130: 465-72.
28. Blacklock CJ, Lawrence JR, Wiles D, et al. Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin. J Clin Path 2001; 54: 553-5.
29. Van der Gaag MS, Van den Berg R, Van den Berg H, Schaafsma G, Hendriks HF,. Moderate consumption of beer, red wine and spirits has counteracting effects on plasma antioxidants in middle-aged men. Eur J Clin Nutr 2000; 54: 286-91.
30. Ridker PM, Fonseca FA, Genest J, et al.; JUPITER Trial Study Group. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007; 100: 1659-64.